Aalto Bio Reagents Scoops Award for Innovator of the Year 2017 for Zika Virus Products
Dublin, Ireland – March 2ndst, 2017 – Aalto Bio Reagents last night received the ‘Innovator of the Year Award’ at the National Small Firms Association(SFA) annual awards. The company was recognized for its Zika virus product portfolio. The award was presented by Enterprise Ireland and the Minister of Employment and Business Mr. Pat Breen in a black-tie ceremony at the RDS in Simmonscourt, Dublin.
Aalto Bio continues to innovate with the recent announcement of its latest tropical disease solution for Yellow Fever, a potentially fatal mosquito-borne flavivirus which is common in tropical and subtropical locations in South America and Africa. Like other flaviruses, such as Zika and Dengue virus, transmission to humans is predominantly via the female Aedes aegypti mosquito. There is no specific treatment for Yellow Fever and, despite access to safe and effective Yellow Fever vaccines; the virus is still causing significant health problems in these countries.
For many infectious diseases, serology assays are the preferred method of patient testing; however, for this sinister virus, early detection is critical to containing the spread of disease. Approximately 15% of infected patients enter what is known as the toxic phase, and this can lead to severe complications such as jaundice, multi-organ failure and even death. Research shows that Yellow Fever virus antigen is present in patients’ blood during the acute phase of illness. These antibodies are unique in that they show no cross-reactivity with other flavivirus NS1 proteins, allowing very specific detection.
Philip Noone, CEO of Aalto Bio Reagents, said “Being presented with this prestigious award as the ‘National Innovator of the Year in 2017’ truly recognizes the hard work and commitment of our great team. We continue to think outside the box for solutions to global infectious disease problems, both emerging and present, and strive to expand our portfolio of products through continuous innovation. With our Zika, Chikungunya, Dengue Triplex and now our Yellow Fever solution we are truly building a comprehensive product listing and enabling our customers to bring superior, best-in-class diagnostic products to market faster, and aid in the development of life-saving vaccines.”
About Aalto Bio Reagents
Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.
Since the company's inception, we have built strong working relationships with our clients who trust us to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base.
For further information please visit http://www.aaltobioreagents.com
Contact: Technical Sales Tel: +353-1-4900685 Email: firstname.lastname@example.org